KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $1.1 billion.

  • Teva Pharmaceutical Industries' Other Accumulated Expenses fell 11.12% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 11.12%. This contributed to the annual value of $1.0 billion for FY2024, which is 2.30% down from last year.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses amounted to $1.1 billion in Q3 2025, which was up 17.34% from $940.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Accumulated Expenses registered a high of $1.2 billion during Q3 2024, and its lowest value of $739.0 million during Q1 2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.0 billion (2024), whereas its average is $1.1 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Other Accumulated Expenses tumbled by 30.35% in 2021, and later rose by 22.75% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Accumulated Expenses (Quarterly) stood at $903.0 million in 2021, then grew by 11.30% to $1.0 billion in 2022, then climbed by 3.88% to $1.0 billion in 2023, then decreased by 2.30% to $1.0 billion in 2024, then fell by 11.12% to $1.1 billion in 2025.
  • Its Other Accumulated Expenses was $1.1 billion in Q3 2025, compared to $940.0 million in Q2 2025 and $964.0 million in Q1 2025.